Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Ambispective, Non Interventional Study of 2 Cohorts (Triple Negative or HR+) of Patients With HER2- Metastatic or Locally Advanced Breast Cancer Treated With Avastin® (Bevacizumab) 1st Line for at Least 12 Months and Without Progression for at Least 12 Months.

NCT01461044 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01461044
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01461044 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Ambispective, Non Interventional Study of 2 Cohorts (Triple Negative or HR+) of Patients With HER2- Metastatic or Locally Advanced Breast Cancer Treated With Avastin® (Bevacizumab) 1st Line for at Least 12 Months and Without Progression for at Least 12 Months.
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Completed
Start date
September 30, 2011
Completion date
November 30, 2013
Enrollment
228 (actual)
Sites
82

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer